Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  stage IV perihilar bile duct cancer
Stage/Subtype:  stage IV perihilar bile duct cancer
Trial Type:  Treatment
Results 1-25 of 27 for your search:
Start Over
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod Before Surgery in Treating Patients With Recurrent or Metastatic Colorectal Cancer That Can Be Removed By Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 10-131, NCI-2013-00076, NCT01545141
Pembrolizumab, Combination Chemotherapy, and Celecoxib in Treating Patients with Advanced Colorectal, Appendix, Gastroesophageal, Pancreatic, or Biliary Tract Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI76239, NCI-2015-00123, 3475-085, 76239, MK-3475 GI, NCT02268825
Regorafenib in Treating Patients With Advanced or Metastatic Biliary Tract Cancer Who Failed First-Line Chemotherapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 13-100, NCI-2014-01117, NCT02053376
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-17651, NCI-2014-00956, 14.02.0015, NCT02115542
Ponatinib Hydrochloride in Treating Patients with Advanced Biliary Cancer with FGFR2 Fusions
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1345, NCI-2014-02075, NCT02265341
Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients with Advanced or Metastatic Biliary Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0524, NCI-2015-00578, NCT02392637
Dasatinib in Treating Patients with Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery and with an IDH Mutation
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-007, NCI-2015-00938, CA180-603, NCT02428855
RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RRx001-27-01, NCI-2015-00944, NCT02452970
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PM1183-B-005-14, NCI-2015-01172, NCT02454972
Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LOXO-TRK-15002, NCI-2015-01947, NCT02576431
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients with Spine Metastases at Risk for Compressing the Spinal Cord
Status: Not yet active
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: 2015-0223, NCI-2016-00683, NCT02713269
Copanlisib, Gemcitabine, and Cisplatin in Treating Patients with Advanced Cholangiocarcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18435, NCI-2016-01029, NCT02631590
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16329, NCI-2016-01171, 2015-004699-31, I3O-MC-JSBF, NCT02711553
Combination Chemotherapy in Treating Patients With Previously Untreated Locally Advanced or Metastatic Gastrointestinal Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0033, NCI-2012-00585, 12-0033-AM010, NCT01643499
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-246, NCI-2015-00892, NCT02024607
Alisertib and Combination Chemotherapy in Treating Patients with Gastrointestinal Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9824, NCI-2014-02475, VICC GI1536, NCT02319018
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 30 and over
Trial IDs: DEK-DKK1-P103, NCI-2015-00597, NCT02375880
Ropidoxuridine in Treating Patients with Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9882, NCI-2015-00258, BRUOG 265, NCT02381561
Afatinib Dimaleate and Capecitabine in Treating Patients with Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 9078, NCI-2015-00684, NCT02451553
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PM60184-A-003-14, NCI-2015-01510, 2014-002943-16, NCT02533674
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients with Metastatic Gastrointestinal Tumors
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0152, NCI-2016-01058, NCT02757391
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16209, NCI-2016-01101, 2015-004421-14, I6F-MC-JJCD, NCT02784795
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients with Unresectable or Metastatic Cholangiocarcinoma
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1542, NCI-2016-01057, NCT02856568
6,8-Bis(benzylthio)octanoic Acid in Treating Patients with Advanced or Metastatic Cholangiocarcinoma that Cannot Be Removed by Surgery
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 to 80
Trial IDs: CCCWFU 59212, NCI-2013-00063, NCT01766219
Start Over